Blueprint Medicines Corp Company Profile (NASDAQ:BPMC)

Blueprint Medicines Corp trades on the NASDAQ under the ticker symbol "BPMC."

Blueprint Medicines Corp (NASDAQ:BPMC) posted its quarterly earnings data on Wednesday, May, 3rd. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.73) by $0.11. The business earned $5.84 million during the quarter, compared to the consensus estimate of $6.02 million. Blueprint Medicines Corp had a negative net margin of 270.30% and a negative return on equity of 55.22%. The firm's revenue was down 14.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.57) earnings per share. View Blueprint Medicines Corp's Earnings History.

7 brokers have issued 1 year price objectives for Blueprint Medicines Corp's stock. Their predictions range from $33.19 to $52.00. On average, they anticipate Blueprint Medicines Corp's stock price to reach $45.74 in the next year. View Analyst Ratings for Blueprint Medicines Corp.

Here are some recent quotes from research analysts about Blueprint Medicines Corp stock:

• 1. According to Zacks Investment Research, "Blueprint Medicines Corp is an oncology company which is engaged in developing kinase inhibitors for genomically defined cancer subsets. Blueprint Medicines Corp is based in Cambridge, MA. " (4/18/2017)
• 2. Jefferies Group LLC analysts commented, "Utilizing its drug discovery platform, BPMC is well positioned to build a balanced pipeline of proprietary & partnered products for cancer/rare disease. Early Ph1 data suggests its two candidates (BLU-285 & BLU-554) are effective & differentiated from current limited tx options, supporting further development." (12/14/2016)
• 3. Cowen and Company analysts commented, "“We are encouraged by the early efficacy seen following BLU-285 administration. BLU-285 has clear activity as evidenced by the observed reductions in serum tryptase and mast cell burden. Safety and tolerability were also good, and provide much room for further dose escalation. We note that BLU-285 has been shown to be safe and well tolerated at doses up to 400mg in GIST, and that dose escalation and longer-term follow up in SM will likely be associated with even more substantial benefit. While it remains to be seen how BLU-285’s profile might stack up relative to other kinase inhibitors including NVS’s midostaurin (pending FDA approval for SM), we expect that more selective and potent inhibition of c-KIT will translate into clinical advantages. We believe advanced SM could represent a >$500MM WW opportunity for BLU-285.”" (12/5/2016)

Blueprint Medicines Corp saw a decline in short interest in the month of April. As of April 13th, there was short interest totalling 1,885,058 shares, a decline of 31.4% from the March 31st total of 2,746,741 shares. Based on an average trading volume of 580,738 shares, the short-interest ratio is currently 3.2 days. Currently, 6.6% of the company's shares are short sold.

Some companies that are related to Blueprint Medicines Corp include Ultragenyx Pharmaceutical (RARE), Clovis Oncology (CLVS), Agios Pharmaceuticals (AGIO), Ligand Pharmaceuticals (LGND), Axovant Sciences Ltd (AXON), Portola Pharmaceuticals (PTLA), Theravance Biopharma (TBPH), Prothena Co. PLC (PRTA), FibroGen (FGEN), Cambrex (CBM), Sarepta Therapeutics (SRPT), Spark Therapeutics (ONCE), Halozyme Therapeutics (HALO), Lexicon Pharmaceuticals (LXRX), Radius Health (RDUS), Array Biopharma (ARRY), Corcept Therapeutics Incorporated (CORT) and Repligen (RGEN).

(BPMC) raised $115 million in an initial public offering (IPO) on Thursday, April 30th 2015. The company issued 7,200,000 shares at $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Blueprint Medicines Corp's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (14.39%), Wellington Management Group LLP (11.49%), BIOTECHNOLOGY VALUE FUND L P (4.90%), Vanguard Group Inc. (3.67%), Alliancebernstein L.P. (2.93%) and Driehaus Capital Management LLC (2.68%). Company insiders that own Blueprint Medicines Corp stock include Christoph Lengauer, Daniel Lynch, Fmr Llc, Jeffrey W Albers, Kevin P Starr, Mark J Levin and Rock Ventures Ii LP Third. View Institutional Ownership Trends for Blueprint Medicines Corp.

Blueprint Medicines Corp's stock was sold by a variety of institutional investors in the last quarter, including Sandia Holdings LLC, Driehaus Capital Management LLC, FIL Ltd, Foresite Capital Management III LLC, Pictet Asset Management Ltd., JPMorgan Chase & Co., Laurion Capital Management LP and SG Americas Securities LLC. Company insiders that have sold Blueprint Medicines Corp stock in the last year include Daniel Lynch, Jeffrey W Albers, Kevin P Starr, Mark J Levin and Rock Ventures Ii LP Third. View Insider Buying and Selling for Blueprint Medicines Corp.

Blueprint Medicines Corp's stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Alliancebernstein L.P., FMR LLC, OppenheimerFunds Inc., Redmile Group LLC, Vanguard Group Inc., Goldman Sachs Group Inc. and Perceptive Advisors LLC. View Insider Buying and Selling for Blueprint Medicines Corp.

Shares of Blueprint Medicines Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Blueprint Medicines Corp stock can currently be purchased for approximately $36.43.